These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23342871)

  • 41. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunology of cutaneous vasculitis associated with both etanercept and infliximab.
    Srivastava MD; Alexander F; Tuthill RJ
    Scand J Immunol; 2005 Apr; 61(4):329-36. PubMed ID: 15853915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tissue effects of anti-TNF therapies.
    D'Haens GR
    Acta Gastroenterol Belg; 2001; 64(2):173-6. PubMed ID: 11475129
    [No Abstract]   [Full Text] [Related]  

  • 48. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment.
    Micu MC; Micu R; Surd S; Gîrlovanu M; Bolboacă SD; Ostensen M
    Rheumatology (Oxford); 2014 Jul; 53(7):1250-5. PubMed ID: 24599921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P; Denier C; Lacroix C; Adams D
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New biologic agents: a critical appraisal.
    Sands BE
    Curr Gastroenterol Rep; 1999 Dec; 1(6):470-5. PubMed ID: 10980988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crohn's disease in patients treated with etanercept.
    Valdivielso Cortázar E; Diz-Lois Palomares MT; Alonso Aguirre P
    Rev Esp Enferm Dig; 2020 Jan; 112(1):80-81. PubMed ID: 31793319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 56. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 58. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD; Clegg DO; Davis JC; Whitmore JB; Solinger A
    J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
    Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nodular fasciitis: a possible side effect of etanercept?
    Vine K; Dacko A; Weinberg JM
    Cutis; 2013 Oct; 92(4):199-202. PubMed ID: 24195093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.